TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00293085
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines.
Study: NCT03145909
Drug: ABBV-176
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00818519
Drug: EE20/Drospirenone (YAZ, BAY86-5300)
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
Study: NCT03522844
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
Study: NCT00003245
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00762853
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush half mouth once with assigned study treatment
Study: NCT00762853
Drug: Fluoride and triclosan
Normalized name: Sodium fluoride and triclosan only product
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush half mouth once with assigned study treatment
Study: NCT01783379
Drug: micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/day infusion in 1 hour
Study: NCT02574910
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
Study: NCT01292005
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
Study: NCT03219216
Drug: Glecaprevir/Pibrentasvir
Normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated tablet
Study: NCT04235894
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous anesthesia with propofol started with 0.5 mg kg-1, and was titrated until a patient was unresponsive to painful stimuli \& maintaining spontaneous breathing during gastrointestinal endoscopy
Study: NCT02332824
Drug: TAK-272
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-272 tablets
Study: NCT02332824
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil tablets
Study: NCT02332824
Drug: Candesartan cilexetil Placebo
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil placebo-matching tablets
Study: NCT00498797
Drug: Zactima (vandetanib)
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00498797
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01596777
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
Study: NCT01596777
Drug: Loperamide placebo
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 ml apple juice
Study: NCT01596777
Drug: Methylnaltrexone placebo
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
Study: NCT01596777
Drug: Methylnaltrexone 12 mg sc.
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
Study: NCT01596777
Drug: Methylnaltrexone IR capsule
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylnaltrexone bromide 500 mg IR capsule
Study: NCT01596777
Drug: Methylnaltrexone ER capsule
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylnaltrexone bromide 500 mg ER capsule
Study: NCT01596777
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg Azulfidine® (Pharmacia)
Study: NCT02985086
Drug: Cefoxitin
Normalized name: Cefoxitin
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02985086
Drug: oxytocin/misoprostol
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03562117
Drug: Gepotidacin
Normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
Study: NCT05811000
Drug: PM012
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PM012 650 mg tablet drug
Study: NCT05811000
Drug: PM012 Placebo
DrugBank: M012 (DB18243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM012 tablet placebo
Study: NCT05811000
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aricept 5 mg (donepezil hydrochloride) drug
Study: NCT05811000
Drug: Donepezil placebo
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aricept 5 mg (donepezil hydrochloride) placebo
Study: NCT03867123
Drug: TMZ
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
Study: NCT01911819
Drug: OSSIF-i sem
Normalized name: iobenguane I-131
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
Study: NCT03370588
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
Study: NCT04008004
Drug: EDP-514
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
Study: NCT04222088
Drug: Arthemeter-lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine (DB06708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)
Study: NCT04222088
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
Study: NCT04222088
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
Study: NCT01071317
Drug: Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg po q day prn headache
Study: NCT00000228
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01151397
Drug: Peg + Vitamin D + Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Peg+ Vitamin D+ Ribavirin for 3 months
Study: NCT01151397
Drug: Peg + Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Peg+ Ribavirin for 6 months
Study: NCT00905255
Drug: Lixisenatide (AVE0010)
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study: NCT01588522
Drug: compound 31543 Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
Study: NCT00004770
Drug: thioctic acid
Normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01897571
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
Study: NCT01865695
Drug: Creon
Normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (\<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
Study: NCT00936065
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
Study: NCT00936065
Drug: Etanercept + Acitretin
Normalized name: Acitretin
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
Study: NCT01897571
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.
Study: NCT00936065
Drug: Acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin at a dose of 10mg BID for 24 weeks
Study: NCT04206618
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 subcutaneous injection daily for 12 months
Study: NCT04206618
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 subcutaneous injection every 6 months for 12 months
Study: NCT03140709
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr
Study: NCT01697956
Drug: BDP
Normalized name: ABDP
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
Study: NCT02716272
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
Study: NCT01256385
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02716272
Drug: Nivolumab + Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
Study: NCT00939211
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation, single dose
Study: NCT00966706
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given systemically
Study: NCT00966706
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given systemically
Study: NCT00966706
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given systemically
Study: NCT00966706
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given systemically
Study: NCT01113593
Drug: Formoterol Fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhalation solution
Study: NCT03031353
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
Study: NCT01428622
Drug: Olodaterol
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aqueous solution
Study: NCT01428622
Drug: Olodaterol & BI54903
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ethanolic solution
Study: NCT00106405
Drug: Memantine HCl
Normalized name: memantine HCl
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003731
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01207453
Drug: Milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
Study: NCT00796835
Drug: ER OROS Paliperidone
Normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04451720
Drug: Risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) injection
Study: NCT06212596
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumour suppressor proteins (TSPs). Selinexor is an oral, first-in-class, potent, slowly reversible, covalent-binding Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks the karyopherin protein Exportin 1 (XPO1), also called chromosome region maintenance 1.
Study: NCT06212596
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
Study: NCT03715634
Drug: SL Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
Study: NCT03715634
Drug: Nalorex
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
Study: NCT02211872
Drug: BI 2536 BS, intravenous
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02312245
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02312245
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02312245
Drug: Topotecan Hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00131404
Drug: taranabant
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
Study: NCT00051753
Drug: levofloxacin; amoxicillin/clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03784222
Drug: Blonanserin
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
Study: NCT01768585
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Please see description of Intervention Arm
Study: NCT00681226
Drug: Ramipril or matching placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Ramipril or matching placebo once daily for 6 months
Study: NCT02571959
Drug: amoxicillin and clavulanic acid
Normalized name: Amoxicillin and clavulanic acid only product
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
Study: NCT02571959
Drug: amoxicillin and clavulanic acid
Normalized name: Amoxicillin and clavulanic acid only product
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
Study: NCT00141271
Drug: Geodon (Ziprasidone)
Normalized name: ziprasidone Injection [Geodon]
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
Study: NCT00141271
Drug: Geodon (Ziprasidone)
Normalized name: ziprasidone Injection [Geodon]
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
Study: NCT02133131
Drug: Grazoprevir/Elbasvir FDC
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
Study: NCT02133131
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir 400mg tablet taken q.d. by mouth.
Study: NCT02070640
Drug: Injection of indocyanine green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
Study: NCT02679781
Drug: oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
Study: NCT02679781
Drug: nasal midazolam
Normalized name: midazolam Nasal Spray
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.